Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of female reproductive system TumorGenesis can provide pharmaceutical companies newfound ability for more effective, expeditious drug development Company is global developer of world-class, … Continue reading →

Predictive Oncology (NASDAQ: POAI), through its Skyline Medical division, is positioned for opportunity in the fluid management systems and accessories market, which is projected to reach $16.1 billion in 2025 from $8.5 billion in 2020, expanding at a CAGR of … Continue reading →

Current POAI Chairman J. Melville (“Mel”) Engle has been appointed to CEO position Engle has held executive positions throughout his career at leading pharma and medical device companies, including Dey L.P. (a subsidiary of Merck KGaA), Allergan, Anika Therapeutics and … Continue reading →

Predictive Oncology (NASDAQ: POAI) is a knowledge-driven company focused on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery. While the pharmaceutical industry has historically invested heavily in genomics and big data, hoping to better understand … Continue reading →

Convergence of AI, big data and biology allows Helomics to test drugs on living tumor tissue rather than artificial systems Helomics model evaluates multiple measurements in powerful multi-omics approach to cancer research Knowledge encapsulated by Helomics AI is “gold dust,” … Continue reading →

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announce the appointment of a new CEO: J. Melville (“Mel”) Engle. Engle is currently serving as chairman of the board and … Continue reading →

Fluid management systems, accessories market forecast at 13.6% CAGR to $16.1 billion by 2025 Skyline Medical’s STREAMWAY(R) System disrupts today’s standard of manually moving waste fluid for disposal STREAMWAY Systems eliminates waste transport, disposal costs, equipment relocation and risk of … Continue reading →

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has reported business highlights and  financial results for the year ended Dec. 31, 2020. Highlights discussed in the report include the … Continue reading →

Cancer screenings, treatments declined during COVID-19 pandemic, highlighting need for personalized therapies to improve outcomes Comprehensive genomic, transcriptomic sequencing of patient samples complete, patient outcome data obtained from UPMC-Magee Project is template for future partnerships with other healthcare institutions to … Continue reading →